Adenosine A2b receptor promotes progression of human oral cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Kasama, Hiroki ^a   Sakamoto, Yosuke ^b   Kasamatsu, Atsushi ^b   Okamoto, Atsushi ^a   Koyama, Tomoyoshi ^a   Minakawa, Yasuyuki ^a   Ogawara, Katsunori ^b   Yokoe, Hidetaka ^c   Shiiba, Masashi ^a   Tanzawa, Hideki ^a,b   Uzawa, Katsuhiro ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2B RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; SHORT HAIRPIN RNA; HIF1A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; IMMORTALIZED CELL LINE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TUMOR VOLUME; UPREGULATION; CELL HYPOXIA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

AGED; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; MOUTH NEOPLASMS; RECEPTOR, ADENOSINE A2B; UP-REGULATION;

EID: 84938081243     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1577-2     Document Type: Article

References (39)

1. Gao ZG, Jacobson KA. Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007;12:479-92.
2. Linden J. Molecular approach to adenosine receptors: receptormediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775-87.
3. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther. 2003;100:31-48.
4. Illes P, Klotz K-N, Lohse MJ. Signaling by extracellular nucleotides and nucleosides. Naunyn-Schmiedebergs Arch Pharmacol. 2000;362:295-8.
5. Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol. 2001;61:443-8.
6. Ma DF, Kondo T, Nakazawa T, Niu DF, Mochizuki K, Kawasaki T, et al. Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol. 2010;41:1550-7.
7. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, et al. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol. 2007;72:395-406.
8. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. 2002;64:993-8.
9. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247-64.
10. Endo Y, Uzawa K, Mochida Y, Shiiba M, Bukawa H, Yokoe H, et al. Sarcoendoplasmic reticulum Ca(2+) ATPase type 2 downregulated in human oral squamous cell carcinoma. Int J Cancer. 2004;110:225-31.
11. Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, Bukawa H, et al. Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med. 2005;16:269-73.
12. Koike H, Uzawa K, Grzesik WJ, Seki N, Endo Y, Kasamatsu A, et al. GLUT1 is highly expressed in cementoblasts but not in osteoblasts. Connect Tissue Res. 2005;46:117-24.
13. Sakuma K, Kasamatsu A, Yamatoji M, Yamano Y, Fushimi K, Iyoda M, et al. Expression status of Zic family member 2 as a prognostic marker for oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2010;136:553-9.
14. Shimizu T, Kasamatsu A, Yamamoto A, Koike K, Ishige S, Takatori H, et al. Annexin A10 in human oral cancer: biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways. PLoS One. 2012;6, e45510.
15. Yamatoji M, Kasamatsu A, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, et al. Dermatopontin: a potential predictor for metastasis of human oral cancer. Int J Cancer. 2012;130:2903-11.
16. Pindborg JJ, Reichart PA, Smith CJ, Waal I. World Health Organization classification of tumours. Histological typing of cancer and precancer of the oral mucosa. 2nd ed. Berlin: Springer; 1997.
17. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. New York: Wiley-Liss; 2009.
18. Shimada K, Uzawa K, Kato M, Endo Y, Shiiba M, Bukawa H, et al. Aberrant expression of RAB1A in human tongue cancer. Br J Cancer. 2005;92:1915-21.
19. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer. 2006;94:717-23.
20. Iyoda M, Kasamatsu A, Ishigami T, Nakashima D, Endo-Sakamoto Y, Ogawara K, et al. Epithelial cell transforming sequence 2 in human oral cancer. PLoS One. 2010;5, e14082.
21. Verburg FA, Wäschle K, Reiners C, Giovanella L, Lentjes EG. Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. Horm Metab Res. 2010;42:736-9.
22. Elzein E, Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008;17:1901-10.
23. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7:759-70.
24. Cristalli G, Müller CE, Volpini R. Recent developments in adenosine A2A receptor ligands. Handb Exp Pharmacol. 2009;193:59-98.
25. Feoktistov I, Biaggioni I. Role of adenosine A2B receptors in inflammation. Adv Pharmacol. 2011;61:115-44.
26. Koeppen M, Eckle T, Eltzschig HK. Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol. 2011;61:145-86.
27. Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17:359-66.
28. Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, et al. Adenosine receptors and cancer. Handb Exp Pharmacol. 2009;193:399-441.
29. Fishman P, Bar-Yehuda S, Ohana G, Pathak S, Wasserman L, Barer F, et al. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur J Cancer. 2000;36:1452-8.
30. Spychal J. Tumor-promoting functions of adenosine. Pharmacol Ther. 2000;87:161-73.
31. Mujoomdar M, Bennett A, Hoskin D, Blay J. Adenosine stimulation of proliferation of breast carcinoma cell lines: evaluation of the [3H] thymidine assay system and modulatory effects of the cellular microenvironment in vitro. J Cell Physiol. 2004;201:429-38.
32. Yamano Y, Uzawa K, Shinozuka K, Fushimi K, Ishigami T, Nomura H, et al. Hyaluronan-mediated motility: a target in oral squamous cell carcinoma. Int J Oncol. 2008;32:1001-9.
33. Shimizu F, Shiiba M, Ogawara K, Kimura R, Minakawa Y, Baba T, et al. Overexpression of LIM and SH3 protein 1 leading to accelerated G2/M phase transition contributes to enhanced tumourigenesis in oral cancer. PLoS One. 2013;8:e83187.
34. Wei Q, Costanzi S, Balasubramanian R, Gao ZG, Jacobson KA. A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal. 2013;9:271-80.
35. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, et al. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol. 2002;119:923-33.
36. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-32.
37. Dammen R, Haugen M, Svejda B, Alaimo D, Brenna O, Pfragner R, et al. The stimulatory adenosine receptor ADORA2B regulates serotonin (5-HT) synthesis and release in oxygen-depleted EC cells in inflammatory bowel disease. PLoS One. 2013;8, e62607.
38. Ning C, Wen J, Zhang Y, Dai Y, Wang W, Zhang W, et al. Excess adenosine A2B receptor signaling contributes to priapism through HIF-1aα mediated reduction of PDE5 gene expression. FASEB J. 2014;28:2725-35.
39. Merighi S, Simioni C, Gessi S, Varani K, Mirandola P, Tabrizi MA, et al. A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia. 2009;11:1064-73.